Compare EMAT & BCTXL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
| Metric | EMAT | BCTXL |
|---|---|---|
| Founded | N/A | N/A |
| Country | United States | Canada |
| Employees | N/A | 4 |
| Industry | | |
| Sector | | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | N/A | N/A |
| IPO Year | N/A | N/A |
| Metric | EMAT | BCTXL |
|---|---|---|
| Price | $9.25 | $1.03 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $30.00 | N/A |
| AVG Volume (30 Days) | ★ 213.0K | 24.0K |
| Earning Date | 01-01-0001 | N/A |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $5.50 | $0.90 |
| 52 Week High | $17.50 | $1.40 |
| Indicator | EMAT | BCTXL |
|---|---|---|
| Relative Strength Index (RSI) | 44.48 | 47.64 |
| Support Level | $5.90 | $0.92 |
| Resistance Level | $11.27 | $1.25 |
| Average True Range (ATR) | 1.91 | 0.11 |
| MACD | 0.16 | 0.00 |
| Stochastic Oscillator | 26.88 | 35.40 |
BriaCell Therapeutics Corp is a clinical-stage biotechnology company focused on developing immunotherapies for cancer treatment, particularly breast cancer. The company's targeted immunotherapy program, Bria-IMT, is a targeted cell-based immunotherapy in end-stage clinical trials aiming to improve outcomes for patients with breast cancer. BriaCell also develops Bria-OTS, personalized off-the-shelf immunotherapies for breast and prostate cancer. BriaCell is involved in clinical collaborations to explore combination therapies for enhanced cancer treatment options.